Sign In
Buy GLTO
$22.20
+0 (+0%)
At Close: Jun 18, 2026
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
04:05pm, Thursday, 21'st Dec 2023
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a c
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
08:00am, Monday, 23'rd Oct 2023
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks Partial response seen in three of five pa
Galecto Announces Plans to Explore Strategic Alternatives
04:01pm, Tuesday, 26'th Sep 2023
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced
Galecto Biotech Collapse: Opportunity For Galectin Therapeutics
08:15am, Thursday, 14'th Sep 2023
Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibiti
Galecto to Present at Investor Conferences in September
11:00am, Thursday, 31'st Aug 2023
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
09:28am, Wednesday, 16'th Aug 2023
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Galecto shares drop 65% as biotech halts development of lung-disease treatment
08:39am, Tuesday, 15'th Aug 2023
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease
Galecto to discontinue development of lung disease treatment
07:55am, Tuesday, 15'th Aug 2023
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study.
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
07:30am, Tuesday, 15'th Aug 2023
Announces next steps for clinical development plan in severe liver diseases Announces next steps for clinical development plan in severe liver diseases
Galecto Reports Second Quarter Operating and Financial Results
04:05pm, Monday, 31'st Jul 2023
BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f
ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc
10:02pm, Thursday, 27'th Jul 2023
On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnology company based in Denmark. This article provides
Galecto to Present at the Upcoming Jefferies Healthcare Conference
08:00am, Tuesday, 30'th May 2023
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi
Galecto to Present Two Posters at AACR Annual Meeting 2023
08:30am, Thursday, 13'th Apr 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for
Orbimed Advisors Now Owns 10.5% of Galecto
10:21pm, Monday, 10'th Apr 2023
Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO).
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
01:33pm, Friday, 11'th Nov 2022
Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
